Cargando…

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19

Angiotensin II (Ang II) may contain a charge relay system (CRS) involving Tyr/His/carboxylate, which creates a tyrosinate anion for receptor activation. Energy calculations were carried out to determine the preferred geometry for the CRS in the presence and absence of the Arg guanidino group occupyi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moore, Graham J., Pires, Jose M., Kelaidonis, Konstantinos, Gadanec, Laura Kate, Zulli, Anthony, Apostolopoulos, Vasso, Matsoukas, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301908/ https://www.ncbi.nlm.nih.gov/pubmed/34356603 http://dx.doi.org/10.3390/biom11070979

Ejemplares similares

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019
por: Swiderski, Jordan, et al.
Publicado: (2023)

Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
por: Ridgway, Harry, et al.
Publicado: (2022)

Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2
por: Matsoukas, John M., et al.
Publicado: (2022)

Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy
por: Ridgway, Harry, et al.
Publicado: (2022)

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System
por: Moore, Graham J., et al.
Publicado: (2022)

Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment
por: Kate Gadanec, Laura, et al.
Publicado: (2021)

Could DIZE be the answer to COVID-19?
por: Qaradakhi, Tawar, et al.
Publicado: (2020)

The Human Myelin Proteome and Sub-Metalloproteome Interaction Map: Relevance to Myelin-Related Neurological Diseases
por: Chasapis, Christos T., et al.
Publicado: (2022)

Glycyrrhizic Acid Inhibits High-Mobility Group Box-1 and Homocysteine-Induced Vascular Dysfunction
por: Gadanec, Laura Kate, et al.
Publicado: (2023)

Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?
por: Gadanec, Laura Kate, et al.
Publicado: (2021)

Facile and Efficient Syntheses of a Series of N-Benzyl and N-Biphenylmethyl Substituted Imidazole Derivatives Based on (E)-Urocanic acid, as Angiotensin II AT1 Receptor Blockers
por: Agelis, George, et al.
Publicado: (2013)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Combination of Taurine and Black Pepper Extract as a Treatment for Cardiovascular and Coronary Artery Diseases
por: Swiderski, Jordan, et al.
Publicado: (2023)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker
por: Forsdyke, Donald R
Publicado: (2015)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin Receptor Blockers Upregulate Angiotensin Type 4 Receptor in Brains of Cognitively Intact Individuals
por: Cosarderelioglu, Caglar, et al.
Publicado: (2021)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
por: Ma, Ye-Ping, et al.
Publicado: (2020)

Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan
por: Matsoukas, John M., et al.
Publicado: (2021)

Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
por: Bae, David J., et al.
Publicado: (2020)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Angiotensin II receptor blockers induce autophagy in prostate cancer cells
por: Woo, Yunseo, et al.
Publicado: (2017)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_blvfspgagr4gp90b6r6536i77p